Clinical trials · Pennsylvania
Cardiomyopathies clinical trials in Pennsylvania
We’re tracking 24 recruiting cardiomyopathies studies with a site in Pennsylvania — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Lancaster, PennsylvaniaAges 18–85 - NCT05180773RecruitingPhase 4
Bromocriptine for new postpartum heart weakness
This trial studies whether bromocriptine improves health outcomes in people recently diagnosed with peripartum cardiomyopathy (a weakened heart during late pregnancy or soon after delivery). You may be asked about timing after childbirth, heart strength tests, and whether you plan to keep breastfeeding.
Allentown, PennsylvaniaAges 18 years+ - NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07210723RecruitingPhase 2/Phase 3
Study of danicamtiv for genetic and familial dilated cardiomyopathy
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07218887RecruitingPhase 1/Phase 2
A study of ALXN2350 for BAG3-related heart muscle disease
This trial tests a new medicine, ALXN2350, for adults whose dilated cardiomyopathy (a weakened, enlarged heart) is caused by a mutation in the BAG3 gene. The goal is to see if it can help the heart pump better.
Philadelphia, PennsylvaniaAges 18–70 - NCT06412666RecruitingPhase 2/Phase 3
Aficamten for teens with obstructive hypertrophic cardiomyopathy
This trial tests a new medicine called aficamten for teenagers with a heart condition that makes the heart muscle too thick and blocks blood flow. The medicine may help make the heart pump more easily and improve symptoms like shortness of breath or chest pain.
Philadelphia, PennsylvaniaAges 12–17 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Philadelphia, PennsylvaniaAges 18–75 - NCT05112237Recruiting
Study of children’s heart disease caused by MYBPC3 gene changes
This is an observational study that follows children under 18 with cardiomyopathy caused by certain MYBPC3 gene mutations. It aims to better understand how the disease changes over time, which may help future treatments be better targeted.
Lancaster, PennsylvaniaAges birth–18 years - NCT05489705Recruiting
Real-world registry for mavacamten and other obstructive HCM treatments
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
Bethlehem, PennsylvaniaAges 18 years+ - NCT05885412RecruitingPhase 1
Study drug for heart rhythm problems in PKP2 heart disease
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Philadelphia, PennsylvaniaAges 18–90 - NCT06688396Recruiting
Finding early signs of dilated cardiomyopathy with AI and mobile screening
This trial uses a smartphone app to screen first-degree relatives of people with dilated cardiomyopathy (DCM) for early signs of the condition. It aims to detect heart muscle weakness before symptoms start, so that treatment can begin sooner.
Lancaster, PennsylvaniaAges 18 years+ - NCT07023614RecruitingPhase 2
Study of Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy
This trial tests an investigational drug (ninerafaxstat) for people with a specific type of thickened heart muscle called non-obstructive hypertrophic cardiomyopathy. The goal is to see if the drug can improve symptoms and exercise ability.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05667493Enrolling by invitationPhase 3
Long-term safety follow-up for eplontersen in ATTR heart disease
This is a long-term study to check the safety of eplontersen over time in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). It is mainly for people who already took the study medication before, or who joined an earlier related study and are doing well.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07207811RecruitingPhase 3
Study of coramitug for heart failure from ATTR amyloidosis
This study tests an investigational medicine called coramitug in people with heart failure caused by ATTR amyloidosis, a condition where abnormal protein builds up in the heart. The goal is to see if it can slow or improve heart function.
Abington, PennsylvaniaAges 18 years+ - NCT05034432RecruitingPhase 4
Test treatment for dangerous heart rhythm episodes in LVAD patients
This trial studies a procedure to fix abnormal heart rhythms (ventricular tachycardia or ventricular fibrillation) in people who have an LVAD and a defibrillator (ICD) or an alternative device. It may help prevent future dangerous rhythm episodes after LVAD treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05650658Recruiting
Compare two heart pacing options in people with weak heart function
This trial compares two types of “left-side” heart pacing to see which one works better in people with weak heart pumping. It may help guide the best pacing choice for improving heart function and symptoms.
Lancaster, PennsylvaniaAges 18 years+ - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
Philadelphia, PennsylvaniaAges 18–75 - NCT06377033Recruiting
Using health records to advance genomic medicine for all
This study uses electronic health records to learn how to improve genomic medicine across a diverse health system. It may help make DNA-based healthcare more accessible and effective for people with certain conditions.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07103057Recruiting
HCM screening registry for people with flagged ECGs
This registry study collects information from people whose ECG tests were flagged by a special computer program as possibly showing hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens. It helps doctors learn more about how well the program works and how it affects patient care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT01790152Recruiting
Dexrazoxane study to monitor heart damage in cancer survivors
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Philadelphia, PennsylvaniaAges Any age - NCT04848506Enrolling by invitationPhase 2/Phase 3
Long-term safety follow-up with aficamten for adults with HCM
This study checks how safe and well-tolerated aficamten is over the long run in adults with hypertrophic cardiomyopathy (HCM). You may be eligible if you finished a prior Cytokinetics aficamten study and your heart pumping strength is in the required range.
Philadelphia, PennsylvaniaAges 18–85 - NCT04520347Enrolling by invitation
Registry for heart rhythm ablation in VT or PVC
This study is a “registry,” meaning it collects information about people undergoing a procedure to treat abnormal heart rhythms like ventricular tachycardia (VT) or premature ventricular contractions (PVCs). It may help researchers better understand which patients benefit from the procedure and how it is done over time.
Philadelphia, PennsylvaniaAges Any age
Cardiomyopathies trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting cardiomyopathies studies listed above.
- University of Pennsylvania · 10 studies
- University of Pittsburgh Medical Center · 5 studies
- Children's Hospital of Philadelphia · 3 studies
- Penn Presbyterian Medical Center · 3 studies
- Clinical Trial Site · 2 studies
- Geisinger · 2 studies
- Lancaster General Hospital · 2 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
What taking part in a cardiomyopathies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cardiomyopathies trials in other states
Common questions
- Are there cardiomyopathies clinical trials in Pennsylvania?
- Yes. We're currently tracking 24 recruiting cardiomyopathies studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cardiomyopathies study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cardiomyopathies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cardiomyopathies studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.